GRAIL, Inc. (GRAL) - Stock Analysis
Last updated: Jan 13, 2026
Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
Robust short-term growth supported by 26-28% revenue growth, rising test volumes, upcoming FDA PMA submission, strategic international investments, and strong technical momentum with a 24.7% price rise over 21 days, while significant losses and cash burn risk temper longer-term upside.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Fundamental Analysis
Key Financial Insights: ⢠Very high liquidity ⢠Persistent losses ⢠Heavy cash burn GRAL has strong liquidity and very low leverage but is generating persistent negative gross margins, heavy cash burn from large R&D and operating losses, and faces sustainability risk without external funding.
Price Behavior
Key Price Behavior Insights: ⢠Steady ascent ⢠Resistance cleared ⢠Earlier pullback Support Level: $100 Resistance Level: $110.39 GRAL has trended higher over the last month, breaking above prior resistance near $100 to hit $105.93 on 2026-01-12, suggesting bullish momentum but with recent volatility risks.
Sentiment & News
Key News Insights: ⢠Institutional inflows ⢠Significant sell-down ⢠JP Morgan presentation Institutional buying (Carnegie, Caxton) alongside a large sell-down (Cwm) and a JP Morgan presentation indicate renewed investor interest in GRAIL but mixed positioning amid a weak small-cap backdrop.
AI Summary
GRAL has shifted from a researchâstage bet to a commercialization execution storyâmaterial testâvolume growth, automationâdriven margin improvement, and an ~$850M runway materially lower survival risk but make PMA approval, reimbursement, and commercial scale the single determinative value drivers. Investors should monitor timely PMA progress, major payer decisions, and sustained margin expansion (can adjusted gross margins hold/improve while scaling) because any regulatory/reimbursement setback or renewed dilution would likely trigger sharp valuation downside.
Description
GRAIL, Inc. is a biotechnology firm based in Menlo Park, California, established in 2015. The company develops blood-based tests intended to detect cancer at early stages in asymptomatic individuals and to support faster diagnostic resolution when cancer is suspected, as well as tests for minimal residual disease and other post-diagnostic uses. GRAIL previously operated as a subsidiary of Illumina, Inc.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Nov 26 | Dec 3 | GRAL | GRAIL, Inc. | Robust short-term growth supported by 26-28% revenue growth, rising test volumes, upcoming FDA PMA submission, strategic international investments, and strong technical momentum with a 24.7% price rise over 21 days, while significant losses and cash burn risk temper longer-term upside. | Closed | -8.1% |